First patient dosed in Adagene’s Phase 2 study of Muzastotug (ADG126) with KEYTRUDA for microsatellite stable colorectal cancer

Adagene Inc. (NASDAQ: ADAG) has officially dosed the first patient in its randomized dose-optimization cohort of the ongoing Phase 2 trial evaluating Muzastotug (ADG126) in combination with Merck & Co.’s KEYTRUDA (pembrolizumab) in patients with microsatellite stable colorectal cancer (MSS CRC) who lack liver metastases. This pivotal milestone reflects the company’s steady clinical momentum and growing recognition within the oncology community for its proprietary SAFEbody precision masking platform — a technology designed to fine-tune immune checkpoint inhibition and reduce off-tumor toxicity.

The Phase 2 study advances one of the most clinically intriguing strategies in solid tumor immunotherapy: combining a tumor-selective anti-CTLA-4 antibody with an established PD-1 inhibitor to unlock durable responses in cancers historically resistant to checkpoint therapy.

How the randomized Phase 2 design sharpens the balance between efficacy and tolerability in “immune-cold” colorectal cancer

The ongoing open-label study features two treatment arms — 10 mg/kg and 20 mg/kg of Muzastotug administered with pembrolizumab — enrolling roughly 30 patients per arm. The primary endpoint focuses on overall response rate (ORR), while secondary measures include duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Adagene’s design intentionally concentrates on MSS CRC patients without liver metastases, a biologically distinct group known to exhibit higher immune responsiveness compared with those who have hepatic involvement.

Earlier Phase 1b/2 results underpin this confidence. In that trial, the 10 mg/kg dose achieved a 17% ORR, while 20 mg/kg produced a 29% ORR — striking figures in a population that typically sees single-digit response rates on PD-1 therapy alone. Even more compelling was the durability of these responses: the median DOR had not yet been reached at data cutoff, and fewer than 20% of participants experienced Grade 3 adverse events. Crucially, no patient discontinued treatment due to toxicity in the 20 mg/kg arm, highlighting the practical safety advantage of the masked antibody design.

By remaining inert in healthy tissue and becoming activated only within the acidic tumor microenvironment, Muzastotug represents a next-generation CTLA-4 approach. This mechanism aims to preserve the deep immune stimulation CTLA-4 inhibitors are known for while minimizing immune-related adverse events that have limited their clinical adoption. In this sense, Adagene’s development strategy positions Muzastotug as both a therapeutic and technological evolution — a refined checkpoint agent built for real-world tolerability.

Why the Muzastotug and KEYTRUDA combination could signal a turning point for microsatellite stable colorectal cancer

Microsatellite stable colorectal cancer is widely viewed as one of the most intractable immunotherapy-resistant malignancies. Roughly 85% of colorectal cancer patients fall into this MSS category, which lacks the high tumor mutational burden or mismatch repair deficiencies that make microsatellite-instable tumors responsive to checkpoint blockade.

By leveraging the dual-checkpoint synergy between a tumor-selective anti-CTLA-4 and a PD-1 inhibitor, Adagene is attempting to “heat up” these cold tumors. The rationale is clear: CTLA-4 inhibition depletes suppressive regulatory T-cells (Tregs) within the tumor, while PD-1 inhibition reactivates exhausted cytotoxic T-cells. The combination therefore reprograms the tumor immune microenvironment from anergic to activated, potentially converting non-responders into responders.

Regulatory alignment has been another cornerstone of the program’s credibility. The U.S. Food and Drug Administration previously provided written feedback in a Type B meeting endorsing the 10–20 mg/kg dose range and the selected patient subset. The FDA also agreed that a monotherapy arm was not required for this stage of study — effectively green-lighting Adagene’s streamlined advancement toward a pivotal dataset. This endorsement reduces clinical uncertainty and signals regulatory confidence in the trial’s scientific rationale and risk-benefit profile.

From a translational science perspective, this strategy reflects an industry-wide shift toward localized immune modulation rather than systemic immune activation. While first-generation CTLA-4 inhibitors such as ipilimumab established proof of concept in melanoma, their safety profiles curtailed wider application. Adagene’s approach aims to revive that powerful mechanism of action under a far safer pharmacologic umbrella.

How investor and institutional sentiment frames Adagene’s evolving position in the immuno-oncology landscape

Institutional sentiment surrounding Adagene has become progressively more constructive as the company continues to de-risk its lead program. Over the past year, the stock (NASDAQ: ADAG) has traded in a range characterized by low volatility but recurring bursts of volume following clinical and regulatory updates. Analysts tracking early-stage biotech innovation increasingly identify Adagene as a platform story — not just a single-asset bet — given that SAFEbody masking can be applied to multiple checkpoint or co-stimulatory targets.

From a capital-markets standpoint, the company’s measured cash management and potential partnership leverage are central themes. Investors view the Phase 2 milestone as a transition from exploratory science to potential value inflection, particularly if upcoming interim data confirm the 20 mg/kg arm’s superior efficacy with sustained tolerability. A positive readout could catalyze discussions with large-cap oncology partners looking to expand combination immunotherapy portfolios beyond PD-1 monotherapy.

Equally important is sentiment across clinical research networks. Oncologists participating in prior cohorts have reported encouraging patient tolerability and manageable immune-related events. If the Phase 2 reproduces these results in a controlled, randomized framework, Adagene could strengthen its clinical narrative heading into 2026–2027 data presentations.

The market’s cautious optimism reflects a maturing biotech narrative: a company steadily progressing from conceptual immunoengineering toward reproducible clinical benefit. The evolution of Adagene’s trial cadence — from early signal discovery to randomized validation — underscores a strategic discipline that institutional investors often reward once consistency in data quality becomes evident.

What the upcoming readouts could mean for checkpoint therapy competition and future immuno-oncology strategy

Beyond its implications for colorectal cancer, this study could redefine expectations for next-generation CTLA-4 therapeutics. If Muzastotug’s tumor-selective mechanism produces sustained tumor regression without systemic toxicity, it may set a new benchmark for combination safety in checkpoint therapy. That in turn could influence how major pharmaceutical companies design future regimens involving PD-1, PD-L1, or TIGIT inhibitors.

The broader competitive context is equally compelling. Multiple biotechs and large pharmas — including Bristol Myers Squibb, AstraZeneca, and BioNTech — are exploring modified CTLA-4 antibodies or fusion constructs to enhance safety and efficacy. However, most candidates remain in early development or show limited differentiation from existing therapies. Adagene’s SAFEbody design, by contrast, introduces a mechanistic edge grounded in spatial control of antibody activation. This differentiation could give it a head start in achieving regulatory and commercial traction, particularly if data continue to show response durability in late-line MSS CRC.

Analysts will also watch whether Adagene expands clinical exploration into patients with liver metastases, an even more refractory group where checkpoint inhibitors have historically underperformed. Positive signals in that subset could significantly enlarge the addressable market. Additionally, the company may leverage the current trial’s biomarker data to refine patient selection, optimizing response prediction across tumor microenvironment phenotypes.

From an industry-wide viewpoint, the success of this program would validate a paradigm in which intelligent antibody design becomes as important as target selection itself. The biotech’s progress therefore holds implications not only for its investors but for the entire next wave of immuno-oncology innovation.

Why Adagene’s patient dosing milestone could mark the inflection point for long-term clinical and commercial value creation

Adagene’s incremental, data-driven advancement of Muzastotug exemplifies a strategy that prioritizes sustainable credibility over short-term hype. By progressing through well-defined regulatory interactions and dose-escalation learnings, the company is methodically positioning itself for either late-stage independence or a potential co-development deal. The dosing of the first patient in this randomized Phase 2 marks more than an operational milestone — it signals clinical maturity.

For the broader biotech ecosystem, this approach reinforces the enduring relevance of CTLA-4 targeting when refined by engineering innovation. As immunotherapy evolves toward personalized, combinatorial frameworks, agents like Muzastotug could serve as adaptable backbones for a variety of tumor settings. Should ongoing trials continue to demonstrate durable efficacy and favorable safety, Adagene may not only revitalize the anti-CTLA-4 category but also emerge as a strategic acquisition candidate for major oncology players seeking differentiated immune-modulation platforms.

In a field crowded by early-stage claims, Adagene’s achievement — first patient dosed in a controlled, regulatory-vetted Phase 2 combination study — stands as a measured but meaningful step forward in the quest to make “cold” tumors treatable.